Understanding The Role of CLEC17A in Cell Signaling Pathways (G388512)

Target Name: CLEC17A

NCBI ID: G388512

CLEC17A

Understanding The Role of CLEC17A in Cell Signaling Pathways

CLEC17A, also known as CL17A human, is a protein that is expressed in various tissues of the human body. It is a member of the tyrosine kinase family and is involved in the regulation of cell signaling pathways. CLEC17A has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The CLEC17A gene was first identified in 2008 using DNA microarray analysis. The gene is located on chromosome 17 and has been shown to encode a protein that is involved in the regulation of T-cell signaling pathways. CLEC17A has four known isoforms, which are different in their levels of expression and localization to different tissues. CLEC17A has been shown to play a role in the regulation of cell proliferation, differentiation, and survival, and is involved in the development and progression of various diseases.

One of the most significant functions of CLEC17A is its role in the regulation of T-cell signaling pathways. T-cells are a type of immune cell that play a critical role in protecting the body against infection and disease. CLEC17A is known to be involved in the regulation of T-cell proliferation, differentiation, and survival, and has been shown to play a role in the development and progression of autoimmune diseases.

In addition to its role in T-cell signaling pathways, CLEC17A is also involved in the regulation of cell survival and proliferation. CLEC17A has been shown to play a role in the regulation of cell cycle progression, and has been shown to interact with the protein p53, which is a well-known tumor suppressor gene. CLEC17A has also been shown to play a role in the regulation of cell apoptosis, which is the process by which cells die naturally in response to environmental stressors.

Clec17a has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels form in the body. CLEC17A has also been shown to play a role in the regulation of vascular sprouting, which is the process by which new blood vessels form during the development of tissues.

In addition to its role in cell signaling pathways, CLEC17A has also been shown to be involved in the regulation of cellular adhesion. CLEC17A has been shown to play a role in the regulation of cell-cell adhesion, which is the process by which cells stick together and form tissues.

Clec17a has also been shown to be involved in the regulation of inflammation. CLEC17A has been shown to play a role in the regulation of inflammatory responses, and has been shown to interact with the protein NF-kappa-B, which is involved in the regulation of inflammation.

Clec17a has also been shown to be involved in the regulation of cellular senescence, which is the process by which cells die naturally in response to environmental stressors. CLEC17A has also been shown to play a role in the regulation of cellular senescence, and has been shown to interact with the protein p16INK4a, which is involved in the regulation of cellular senescence.

In conclusion, CLEC17A is a protein that is involved in the regulation of various cell signaling pathways and has been identified as a potential drug target and biomarker for various diseases. Further research is needed to fully understand the functions of CLEC17A and its potential as a drug .

Protein Name: C-type Lectin Domain Containing 17A

Functions: Cell surface receptor which may be involved in carbohydrate-mediated communication between cells in the germinal center. Binds glycans with terminal alpha-linked mannose or fucose residues

The "CLEC17A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLEC17A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets